$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent deal-making has brought larger, deeper-pocketed players into the IPF space, but Promedior still likes its approach of going it alone with Pentraxin-2-based therapies in fibrotic disease.
You may also be interested in...
Bristol’s Fibrotic Game Plan: Promedior Acquisition Hinges On Phase II Results
Bristol’s third deal in anti-fibrosis field in past year could give it intravenous, disease-modifying candidate for myelofibrosis and idiopathic fibrosis.
After Pirfenidone: Broad Competition To Bring First Therapy For Underlying Cause Of IPF To Market
In the latest in “The Pink Sheet”’s market snapshot series, InterMune continues to work on getting pirfenidone approved in the U.S., while several companies are developing next-stage therapies for IPF.
Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle
Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.